Education
About Us
Working with TipRanks
Follow Us
Alzinova AB (DE:78D)
:78D
78D Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.11 - €0.38
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€16.44M
Enterprise Value€169.13M
Total Cash (Recent Filing)€3.59M
Total Debt (Recent Filing)kr800.00K
Price to Earnings (P/E)―
Beta-0.86
Next Earnings
Aug 21, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding104,323,586
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.47
Price to Book (P/B)1.24
Price to Sales (P/S)0.00
P/FCF Ratio-5.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
78D FAQ
What was Alzinova AB’s price range in the past 12 months?
Alzinova AB lowest stock price was €0.11 and its highest was €0.38 in the past 12 months.
What is Alzinova AB’s market cap?
Alzinova AB’s market cap is €16.44M.
When is Alzinova AB’s upcoming earnings report date?
Alzinova AB’s upcoming earnings report date is Aug 21, 2025 which is in 24 days.
How were Alzinova AB’s earnings last quarter?
Currently, no data Available
Is Alzinova AB overvalued?
According to Wall Street analysts Alzinova AB’s price is currently Overvalued.
Does Alzinova AB pay dividends?
Alzinova AB does not currently pay dividends.
What is Alzinova AB’s EPS estimate?
Alzinova AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alzinova AB have?
Alzinova AB has 104,323,586 shares outstanding.
What happened to Alzinova AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Alzinova AB?
Currently, no hedge funds are holding shares in DE:78D
Company Description
Alzinova AB
Alzinova AB (publ), a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease; and ALZ-201, a monoclonal antibody that is used for the treatment of toxic Aß oligomers. The company was founded in 2011 and is based in Mölndal, Sweden.
Technical Analysis
Elicera Therapeutics AB
―
Ascelia Pharma AB
―
Active Biotech AB
―
NextCell Pharma AB
―
CombiGene AB
―